Zyclara (imiquimod)

P1, N=300, Enrolling by invitation, M.D. Anderson Cancer Center | Recruiting --> Enrolling by invitation

Resiquimod suppressed B16 melanoma growth, with an effect superior to that of imiquimod...In patient-derived organoids and melanoma slice cultures, resiquimod induced significant tumor killing and CD8+ T cell activation, further augmented by PD-1 antibodies. Our findings support the conclusion that resiquimod promotes CD8+ T-cell priming via dendritic cells and enhances the therapeutic efficacy of anti-PD-1 checkpoint blockade in melanoma.

RrcHSIL non-responders to imiquimod exhibited an even more immunosuppressive microenvironment than complete responders, characterized by increased infiltration of CD4 + FoxP3 + regulatory T cells and (CD14 + )CD68 + CD163 + M2-like macrophages and CD14 + HLADR- monocytic myeloid derived suppressor cells. The limited efficacy of imiquimod in rrcHSIL may be explained by a strong immunosuppressive microenvironment.

DHU-OH-6 enables fluorescence imaging of exogenous and endogenous HOCl in cells and provides fluorescence-guided therapy in an imiquimod-induced psoriasis mouse model, where it alleviates psoriatic skin lesions and mitigates systemic toxicity relative to free CPT. This HOCl-activated hydroxyl drug-release platform offers a generalizable strategy for the design of site-selective, image-guided prodrugs for HOCl-overexpressing diseases.

Mice were divided into five groups: control (cream base), imiquimod (IMQU; 62.5 mg/day for 7 days), a commonly used inducer of psoriasis-like dermatitis, standard (tacrolimus 20 mg/kg/day, 2 h after IMQU), IMQU + D...These findings suggest that D. tortuosa and D. triradiata NCs possess promising anti-psoriatic potential, through immunomodulatory and anti-inflammatory mechanisms, with D. tortuosa demonstrating superior efficacy. They may serve as effective natural alternatives to conventional psoriasis treatments.

Here, we determined and compared the efficacy of sodium R-lipoate (NaRLA, 50 and 100 mg/kg body weight/day), given orally for 8 consecutive days, in a BALB/c mouse model of imiquimod-induced psoriatic skin inflammation, in comparison with the synthetic drug methotrexate (MTX). Furthermore, NaRLA resulted in a significant improvement (P < 0.001) on both Evans blue extravasation and mast cell degranulation, suggesting a reduction in inflammation and edema. Thus, our observations imply that NaRLA may serve as an effective agent for alleviating psoriatic skin inflammation via targeting IL-23/IL-17A axis and mast cell degranulation.

In a rat collagen-induced arthritis model, anti-TL1A antibody treatment effectively reduced arthritis severity, with similar efficacy to the TNF antagonist etanercept. In humanized mouse Imiquimod-induced psoriasis and 2,4,6‑trinitrobenzene sulfonic acid colitis models, anti-TL1A demonstrated similar efficacy to anti-IL-23 and anti-TNF antibodies. These findings characterize two novel extended half-life TL1A antibodies and support the ongoing Phase 2 clinical development of SPY002 and SPY072 for immune-mediated diseases such as inflammatory bowel disease and rheumatic diseases.

P3, N=1630, Not yet recruiting, VA Office of Research and Development | Trial completion date: May 2032 --> Aug 2032 | Trial primary completion date: May 2032 --> Aug 2032

P4, N=40, Active, not recruiting, University of Michigan | Recruiting --> Active, not recruiting | Trial completion date: Sep 2027 --> May 2026 | Trial primary completion date: Mar 2027 --> May 2026

Results showed that Khib modification levels at the K42 site of ACTR3 were significantly reduced in lesional tissues from psoriatic patients and imiquimod (IMQ)-induced psoriatic mice...Notably, TAK1 antagonists effectively reversed abnormal keratinocyte proliferation and psoriatic inflammation induced by the ACTR3 K42A mutation. This study elucidates that reduced Khib modification at the ACTR3 K42 locus promotes keratinocyte proliferation via regulation of the TAK1-MK2-HSP27 signalling pathway, offering a previously undescribed molecular insight into psoriasis pathogenesis.

TLR3 and TLR7 agonists induce IFN-driven monocyte activation in PWH, which is effectively modulated by JAK-STAT inhibitors. These findings support their potential as therapeutic agents to mitigate inflammation in chronic HIV infection.

P1, N=25, Recruiting, Northwestern University | Trial completion date: Feb 2026 --> Dec 2027 | Trial primary completion date: Aug 2025 --> Jun 2027